Therapeutic amenorrhea in patients at risk for thrombocytopenia

Obstetrical and Gynecological Survey

Volumn 63, Issue 6, 2008, Pages 395-402

  Martin Johnston, Meredith K ^a   Okoji, Qlanma Y ^b   Armstrong, Alicia ^c  

^a ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; DANAZOL; DOXORUBICIN; ESTROGEN; ESTROGEN DERIVATIVE; GONADORELIN AGONIST; LEUPRORELIN; LEVONORGESTREL; LIPID; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; ANTIESTROGEN; CONTRACEPTIVE AGENT; GONADORELIN;

ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ASTHENIA; BILIRUBIN BLOOD LEVEL; CONTRACEPTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM ABLATION; HAIR LOSS; HEADACHE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERMENORRHEA; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID BLOOD LEVEL; LIVER TOXICITY; MENORRHAGIA; MORBIDITY; MYALGIA; NAUSEA; OSTEOLYSIS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN; ADULT; COMORBIDITY; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MENSTRUATION;

ADULT; COMORBIDITY; CONTRACEPTIVE AGENTS, FEMALE; DANAZOL; ESTROGEN ANTAGONISTS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYSTERECTOMY; INTRAUTERINE DEVICES; LEVONORGESTREL; MENORRHAGIA; MENSTRUATION; THROMBOCYTOPENIA;

EID: 54749089270     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181706620     Document Type: Review

References (75)

1. Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 1993;269: 1823-1828.
2. Vessey MP, Villard-Mackintosh L, McPherson K, et al. The epidemiology of hysterectomy: findings in a large cohort study. Br J Obstet Gynaecol 1992;99:502-1407
3. Rees M. Menorrhagia. BML 1987;294:759-763.
4. 4. Meirow D, Rabinovici J, Katz D, et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006;107:1634-1641. (Pubitemid 44546925)
5. Trasi SA, Pathare AV, Shetty SD, et al. The spectrum of bleeding disorders in women with menorrhagia: a report from Western India. Ann Hematol 2005;84:339-342.
6. 6. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998;351:485-489. (Pubitemid 28070095)
7. Pasoto SG, Mendonça BB, Bonfa E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002;11:175-180.
8. Silva CAA, Leal MM, Leone C, et al. Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 2002;11:419-425.
9. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007.
10. CA Cancer J Clin 2007;57:43-66.
11. Surveillance, Epidemiology, and End Results. Available at: http://seer.cancer.gov/.
12. 11. Pearce MS, Parker L, Windebank KP, et al. Cancer in adolescents and young adults aged 15-24 years: a report from the north of England young person's Malignant Disease Registry, UK. Pediatr Blood Cancer 2005;45:687-693. (Pubitemid 41279361)
13. 12. Ghalie R, Porter C, Radwanska E, et al. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol 1993;42: 350-353. (Pubitemid 23104805)
14. Clarke K, Basser RL. The role of platelet growth factors in cancer therapy. Stem Cells 1996;14(suppl 1):274-280.
15. Brown JR, Demetri GD. Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep 2002;1:110-118.
16. Alvarez do Barrio M, Gonzalez Diez R, Hernandez Sanchez JM, et al. Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 2005;10:20-22.
17. Lachritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333: 1721-1725.
18. Vrielink H, Reesink HW. Transfusion-transmissible infections. Curr Opin Hematol 1998;5:396-405.
19. Blajchman MA, Gold M. Bacterial contamination of platelet concentrates: incidence, significance, and prevention. Semin Hematol 2001 ;38:20-26.
20. Demers C, Derzko C, David M, et al. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006;95:75-87.
21. Kingman CEC, Kadir RA, Lee CA, et al. The use of levonorgestrelreleasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004;111: 1425-1428.
22. 21. Lhomme C, Brault PH, Bourhis JH, et al. Prevention of menstruation with leuprorelin (GnRH Agonist) in women undergoing myelosuppresive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study. Leuk Lymphoma 2001;42:1033-1041. (Pubitemid 32827525)
23. 22. Chiusolo P, Salutari P, Sica S, et al. Luteinizing hormonereleasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplant 1998;21:821-823. (Pubitemid 28190627)
24. Ambriz R, Pizzuto J, Morales M, et al. Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). Nouv Rev Fr Hematol 1986;28:275-279.
25. De Leo V, La Marca A, Morgante G. Short-term treatment of uterine fibromyomas with danazol. Gynecol Obstet Invest 1999;47:258-262.
26. 25. La Marca A, Musacchio MC, Morgante G, et al. Homodynamic effect of danazol therapy in women with uterine leiomymomata. Fértil Steril 2003;79:1240-1242. (Pubitemid 36547871)
27. Beaumont H, Augood C, Duckitt K, et al. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2002;(2): CD001017.
28. Dunphy BC, Goerzan J, Greene CA, et al. A double-blind randomized study comparing danazol and medroxyprogesterone acetate in the management of menorrhagia. J Obstet Gynaecol 1998;18:553-555.
29. De Leo V, Morgante G, La Marca A, et al. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Saf 2002;25:759-779.
30. Protheroe J. Modern management of menorrhagia. J Fam Plann Reprod Health Care 2004;30:118-122.
31. 30. Van Laar JM, Tyndall A. Intense immunosuppression and stemcell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control 2003;10:57-65. (Pubitemid 36231963)
32. Amsterdam A, Jakubowski A, Castro-Malaspina H, et al. Treatment of menorrhagia in women undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34:363-366.
33. 32. Kadir RA, Lukes AS, Kouides PA, et al. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertil Steril 2005;84:1352-1359. (Pubitemid 41571881)
34. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgesterel-releasing intrauterine system or hysterectomy for treatment of menorrhagia. JAMA 2004;291:1456-1463.
35. Lethaby AE, Cooke I, Rees M. Progesterone or progestogenreleasing intrauterine systems for heavy menstrual bleeding (review). Cochrane Database Syst Rev 2005;(19):CD002126.
36. Mercorio F, De Simone R, Di Spievio Sardo A, et al. The effect of a levonorgestrel-releasing intrauterine treatment of myomarelated menorrhagia. Contraception 2003;67:277-280.
37. 36. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest 2005;59:29-35. (Pubitemid 40082294)
38. 37. Soysal M, Soysal S, Ozer S. A randomized controlled trial of levonorgesterel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. Zentralbl Gynakol 2002;124: 213-219. (Pubitemid 34680132)
39. Wildemeersch D, Schacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Obstet Gynecol Reprod Biol 2002;102:74-79.
40. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005;353:2539-2549.
41. 40. Sinei SK, Morrison CS, Sekadde-Kigondu C, et al. Complications of use of intrauterine devices among HIV-1-infected women. Lancet 1998;351:1238-1241. (Pubitemid 28181963)
42. Paladine HL, Blenning CE, Judkins DZ, et al. Clinical inquiries. What are contraindications to IUDs? J Fam Pract 2006;55: 726-729.
43. 42. Zerner J, Doil KL, Drewry J, et al. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med 1981;26:99-102. (Pubitemid 11056672)
44. 43. Fong Y, Singh K. Effect of the levonorgesterol-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception 1999;60:51-53. (Pubitemid 29505356)
45. Farley TM, Rosenberg MJ, Rowe PJ, et al: Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-788.
46. American College of Obstetricians and Gynecologists. Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin #73. Obstet Gynecol 2006;107:1453-1472.
47. 46. Golschmidt N, Linetcsky E, Shalom E, et al. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003;98:1239-1242. (Pubitemid 37099909)
48. Ziegler S, Sperr WR, Knobl P, et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005;115:59-64.
49. Marras LC, Geerts W, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 2000;89:640-646.
50. Lin J, Proctor MC, Varma M, et al. Factors associated with recurrent venous thromboembolism in patients with malignant disease. J Vase Surg 2003;37:976-983.
51. World Health Organization: improving access to quality care in family planning. Medical Criteria for Contraceptive Use. 3rd ed. Geneva: WHO; 2004.
52. 51. Ma B, Yeo W, Hui P, et al. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer-a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002;62:185-189. (Pubitemid 34286451)
53. Neinstein L. Contraception in women with special medical needs. Compr Ther 1998;24:229-250.
54. Connolly TJ, Zuckerman AL. Contraception in the patient with liver disease. Semin Perinatal 1998;22:178-182.
55. 54. Haimov-Kochman R, Ackerman Z, Anteby EY. The contraceptive choice for a Wilson's disease patient with chronic liver disease. Contraception 1997;56:241-244. (Pubitemid 27516391)
56. 55. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003;101:653-661. (Pubitemid 36390051)
57. Anderson FD, Hait H. A multicenter randomized study of an extended cycle oral contraceptive. Contraception 2003;68: 89-96.
58. Hitchcock CL, Prior JC. Evidence about extending the duration of oral contraceptive use to suppress menstruation. Womens Health Issues 2004;14:201-211.
59. Speroff L, Fritz MA. Dysfunctional uterine bleeding. In: Clinical Gynecologic Endocrinology and Infertility. 7th ed. New York: Lippincott Williams & Wilkins; 2005:558-559.
60. 59. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systemic review. Obstet Gynecol Surv 2002;57:120-128. (Pubitemid 34132150)
61. 60. Stewart A, Cummins C, Gold L, et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systemic review. BJOG 2001;108:74-86. (Pubitemid 32102607)
62. Lahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomized study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998;316:11221126.
63. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998;105:592-598.
64. 63. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril 2001;76:304-309. (Pubitemid 32703819)
65. Romer T. Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea. Eur J Obstet Gynecol Reprod Biol 2000;90:27-29.
66. 65. Kriplani A, Singh BM, LaI S, et al. Efficacy, acceptability, and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet 2007;97:190-194. (Pubitemid 46733985)
67. 66. Kaunitz AM, Stern L, Doyle J, et al. Use of the levonorgestrelIUD in the treatment of menorrhagia: improving patient outcomes while reducing the need for surgical management. Manag Care Interface 2007;20:47-50. (Pubitemid 46481958)
68. 67. Hurskainen R, Paavonen J. Levonorgestrel-releasing intrauterine system in the treatment of heavy bleeding. Curr Opin Obstet Gynecol 2004;16:487-490. (Pubitemid 41015900)
69. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002;99:229-234.
70. National Center for Health Statistics. Health-United States, 1995. Hyattsville, MD: US Department of Health and Human Services, Public Health Service, CDC, National Center for Health Statistics; 1995.
71. Leung PL, Ng PS, Lok IH, et al. Puberty menorrhagia secondary to inherited bleeding disorders. Acta Obstet Gynecol Scand 2005;84:921-922.
72. Aberdeen endometrial ablation trials group. A randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcomes at four years. BJOG 1999;106:360-366.
73. El-Nashar SA, Hopkins MR, Feitoza SS, et al. Global endometrial ablation for menorrhagia in women with bleeding disorders. Obstet Gynecol 2007;109:1381-1387.
74. O'Connor H, Magos A. Endometrial resection for the treatment of menorrhagia. N Engl J Med 1996;335:151-156.
75. Keshavarz H, Hillis SD, Kieke BA, et al. Hysterectomy surveillance-United States, 1994-1999. MMWR Surveill Summ 2002;51:1-8.